ClinicalTrials.gg
CompletedNCT06149104Updated Oct 14, 2025Results posted

A Safety Study of Sacubitril/Valsartan in Japanese Pediatric Patients With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction Who Have Completed CLCZ696B2319E1 Study

A Phase 3 interventional study of sacubitril/valsartan in Heart Failure, sponsored by Novartis Pharmaceuticals. Completed at 6 sites in Japan. Open to participants aged 3 Years to 18 Years. Per ClinicalTrials.gov, last updated 2025-10-14.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
3 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 24 studies testing sacubitril in Heart Failure — 5 open to participants now, 5 under way, 2 of them phase 3. sacubitril · Heart Failure.

Enrollment
20th of 24
8 · median 104
Started
2023
with 1 other
Phase 3
7 of 24
2 open now
Registered
19th of 24
by date
Lead sponsor
5 of 24
Novartis Pharmaceuticals

Among the 24 studies testing sacubitril in Heart Failure, this one is the 20th largest by enrollment, is one of 2 that started in 2023, is one of 7 in phase 3, and was the 19th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,392 are open to participants now.

Browse Heart Failure studies →

Open to participants now

5 of the 24 studies testing sacubitril in Heart Failure are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About sacubitril

sacubitril: first FDA approval 2015 (ENTRESTO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 966 Heart Failure studies recruiting now, 689 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 3 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing sacubitril in Heart Failure, or all of them as a file.
02

Study summary

The purpose of this open-label study was to collect additional safety information of sacubitril/valsartan and to provide post-trial access to sacubitril/valsartan for the eligible Japanese patients who completed CLCZ696B2319E1(NCT03785405) study until marketed product of pediatric formulation, film-coated granules in capsule, is available in Japan.

Read the detailed description

This trial (CLCZ696B2319E2) was a multicenter, open-label extension study for Japanese patients who have successfully completed the CLCZ696B2319E1 study. Only Japanese patients who successfully completed CLCZ696B2319E1 study and fulfilled protocol requirements were eligible to participate in this study.

The first visit (Visit Day1) was the same day as the End of Study visit of CLCZ696B2319E1 study.

03

Conditions studied

  • Heart Failure

Browse trials for

Keywords

  • sacubitril/valsartan
  • post-trial access
  • pediatric
  • heart failure
04

Who can participate

Ages eligible
3 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed
  • \<18 years of age (at the time of signing informed consent)
  • Completed CLCZ696B2319E1 study and safely enrolled

Exclusion criteria

Exclusion Criteria:

  • Permanently discontinued the study treatment during CLCZ696B2319E1 study
  • Renal vascular hypertension (including renal artery stenosis)
  • History of angioedema
  • Having parents or legal guardians who do not give consent or allow the child to give assent, or inability of patient or the parents/legal guardians to follow instructions or comply with follow-up procedures
  • Any medical condition(s) that may put the patient at risk in the Investigator's opinion or that the Investigator deems unsuitable for the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    sacubitril/valsartan

    The starting dose of study drug was determined by the investigator in consideration of the participant´s condition. The dose level at the end of study visit of CLCZ696B2319E1 study could remain the same, or the dose level could be changed at the discretion of the investigator.

    Drug: sacubitril/valsartan

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Number of participants with treatment emergent adverse events (any AE regardless of seriousness), and SAEs.

    Time frame: Adverse events were reported from first dose of study treatment until end of study treatment, up to a maximum duration of approximately 8 months.

07

Results

Posted Feb 18, 2025

Participant flow

Participants took part in 6 investigative sites in Japan.

Participant flow — Overall Study
MilestoneSacubitril/Valsartan
Started8
Completed8
Not completed0

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

Number of participants with treatment emergent adverse events (any AE regardless of seriousness), and SAEs.

Time frame:
Adverse events were reported from first dose of study treatment until end of study treatment, up to a maximum duration of approximately 8 months.
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsSacubitril/Valsartan
Adverse Events6
Serious Adverse Events1

Adverse events

Collected over Adverse events were reported from first dose of study treatment until end of study treatment, up to a maximum duration of approximately 8 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sacubitril/Valsartan0/8 (0%)1/8 (12.5%)6/8 (75%)
All Patients0/8 (0%)1/8 (12.5%)6/8 (75%)
Most frequent serious events
Most frequent serious events
EventSacubitril/ValsartanAll Patients
Upper respiratory tract infectionInfections and infestations1/81/8
AsthmaRespiratory, thoracic and mediastinal disorders1/81/8
Most frequent other events
Showing 10 of 14
Most frequent other events
EventSacubitril/ValsartanAll Patients
NasopharyngitisInfections and infestations2/82/8
VomitingGastrointestinal disorders1/81/8
Seasonal allergyImmune system disorders1/81/8
COVID-19Infections and infestations1/81/8
GastroenteritisInfections and infestations1/81/8
InfluenzaInfections and infestations1/81/8
Otitis mediaInfections and infestations1/81/8
Streptococcal infectionInfections and infestations1/81/8
Upper respiratory tract infectionInfections and infestations1/81/8
Urinary tract infectionInfections and infestations1/81/8

Baseline characteristics

Age, Continuous
Age, Continuous(years)Sacubitril/Valsartan
Mean6.75 ± 4.234
Sex: Female, Male
Sex: Female, Male(Participants)Sacubitril/Valsartan
Female6
Male2
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Sacubitril/Valsartan
Asian8
08

Study locations

6 sites
  • Novartis Investigative Site
    Ōbu, Aichi-ken 474 8710, Japan
  • Novartis Investigative Site
    Ōmura, Nagasaki 856-8562, Japan
  • Novartis Investigative Site
    Bunkyo Ku, Tokyo 113 8655, Japan
  • Novartis Investigative Site
    Setagaya-ku, Tokyo 157-8535, Japan
  • Novartis Investigative Site
    Saitama, 330 8777, Japan
  • Novartis Investigative Site
    Toyama, 930-0194, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2023 to primary completion in Aug 2024, 8 months.

Results were first posted in Feb 2025, 6 months after primary completion.

Of 63 industry-sponsored phase 3 interventional studies under Heart Failure, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 44. This study's 8 months is below that.

Counting every sponsor, half of 151 studies reached it within 39 months; a quarter within 25 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2023
First posted
Nov 28, 2023
StartActual
Dec 4, 2023
Primary completionActual
Aug 14, 2024
CompletionActual
Aug 14, 2024
Results first posted
Feb 18, 2025
Last update
Oct 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06149104
Responsible party
Sponsor
First posted
Nov 28, 2023
Start date
Dec 4, 2023
Primary completion
Aug 14, 2024
Completion
Aug 14, 2024
Results posted
Feb 18, 2025
Last update
Oct 14, 2025

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sacubitril · Valsartan

Start the discussion